BACKGROUND: Cost containment measures in hospitals suspect the efficiency of 5-HT3-receptor antagonists (5-HT3-RA) in treating chemotherapy-induced emesis. RESEARCH: This paper compares the cost-efficacy of acute antiemetic interventions both for high and moderate emetogenic cancer treatments. The cost-efficacy-analysis is based on a recent metaanalysis comparing metoclopramide (MCP)- and 5-HT3-RA-containing antiemetic regimens both in comedication with corticosteroids. Total costs for treating moderate emetogenic cancer treatments sum up to DM 53.- for MCP-regimens and DM 55.- for 5-HT3-RA resp. In high emetogenic cancer treatments total costs for MCP-regimens are DM 76.- and DM 61.- for 5-HT3-RA. Total costs for fully controlled patients in moderate emetogenic cancer treatments are DM 77.- for MCP and DM 71.- for 5-HT3-RA. In high emetogenic cancer treatments costs for the fully controlled patient with MCP-regimens are DM 126.- and DM 79.- with 5-HT3-RA. CONCLUSION: Even under mere economical considerations 5-HT3-RAs should be prescribed in treating acute chemotherapy-induced emesis.
BACKGROUND: Cost containment measures in hospitals suspect the efficiency of 5-HT3-receptor antagonists (5-HT3-RA) in treating chemotherapy-induced emesis. RESEARCH: This paper compares the cost-efficacy of acute antiemetic interventions both for high and moderate emetogenic cancer treatments. The cost-efficacy-analysis is based on a recent metaanalysis comparing metoclopramide (MCP)- and 5-HT3-RA-containing antiemetic regimens both in comedication with corticosteroids. Total costs for treating moderate emetogenic cancer treatments sum up to DM 53.- for MCP-regimens and DM 55.- for 5-HT3-RA resp. In high emetogenic cancer treatments total costs for MCP-regimens are DM 76.- and DM 61.- for 5-HT3-RA. Total costs for fully controlled patients in moderate emetogenic cancer treatments are DM 77.- for MCP and DM 71.- for 5-HT3-RA. In high emetogenic cancer treatments costs for the fully controlled patient with MCP-regimens are DM 126.- and DM 79.- with 5-HT3-RA. CONCLUSION: Even under mere economical considerations 5-HT3-RAs should be prescribed in treating acute chemotherapy-induced emesis.
Authors: A Stewart; B McQuade; J D Cronje; L Goedhals; A Gudgeon; L Corette; X Froger; M Tubiana-Hulin; P Laplaige; J T Roberts Journal: Oncology Date: 1995 May-Jun Impact factor: 2.935
Authors: C Seynaeve; J Schuller; K Buser; H Porteder; S Van Belle; P Sevelda; D Christmann; M Schmidt; H Kitchener; D Paes Journal: Br J Cancer Date: 1992-07 Impact factor: 7.640